Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2014, Pages

  Goyal, Vikas ^a   Chang, Anne B ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; PLACEBO; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

BRONCHIECTASIS; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; REVIEW; SYSTEMATIC REVIEW; TRANSITION DYSPNEA INDEX; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; CHILD; DISEASE COURSE; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; BRONCHIECTASIS; BUDESONIDE; CHILD; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84919812715     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010327.pub2     Document Type: Review

References (36)

1. Martínez-García MA, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest February 2012;141(2):461-8. 3069762
2. Ding H, Wang JG, Sun XY, Xu LJ. Responsibility to bronchodilator and glucocorticosteroid in patients with bronchiectasia and reversible airflow limitation. Journal of Jilin University Medicine Edition 2006;32(5):872-5. 3069764
3. Mostafapour E, Mousavi S-AJ, Shahmiri SS, Fereshtehnejad S-M. Effects of combination of fluticasone propionate and salmeterol xinafoate on lung function improvement in patients with bronchiectasis. Lijecnicki Vjesnik 2009;131(Suppl 6):8-11. 3069766
4. Khodosh E, Poteiko P, Krutko V, Khoroshun D. Influence of inhaled glucocorticosteroids on course of the bronchiectasis. European Respiratory Journal 2015;46(Suppl 59):PA2963. 6614815
5. Thongmak P, Piyavisetpat N, Wongtim S, Kawkitinarong K. Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis. European Respiratory Journal 44(Suppl 58):P953 (available from http://erj.ersjournals.com/content/44/Suppl_58/P953.abstract). 6614817
6. Cates C. Visual Rx. Online NNT Calculator. Cates C, 2003.
7. Cazzola M, Calzetta L, Matera MG. Beta(2) -adrenoceptor agonists: current and future direction. British Journal of Pharmacology 2011;163:4-17.
8. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non-CF bronchiectasis-clinical and HRCT evaluation. Pediatric Pulmonology 2003;35(6):477-83.
9. Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: Thoracic Society of Australia and New Zealand and Australian Lung Foundation Position Statement. Medical Journal of Australia 2010;193(6):356-65.
10. Chang AB. Editorial. Bronchiectasis: so much yet to learn and to do. Paediatric Respiratory Review 2011;12:89-90.
11. Chroinin MN, Greenstone I, Lasserson TJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD005307.pub2]
12. Ducharme FM, Ni CM, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
13. Franco F, Sheikh A, Greenstone M. Short acting beta2-agonists for bronchiectasis. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003572]
14. Gupta S, Siddiqui S, Haldar P, Raj JV, Entwisle JJ, Wardlaw AJ, et al. Qualitative analysis of high resolution computed tomography scans in severe asthma. Chest 2009;136(6):1521-8.
15. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?. Heart and Lung 2006;35(1):58-65.
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
17. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000996.pub2]
18. Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. European Respiratory Journal 1997;10(12):2784-7.
19. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in adult bronchiectasis. COPD 2005;2(1):27-34.
20. King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Internal Medicine Journal 2006;36(11):729-37.
21. Lewis MM, Mortelliti MP, Yeager H, Tsou E. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 2002;19(2):154-9.
22. Müsellim B. Bronchial hyperreactivity in non-cystic fibrosis bronchiectasis. Journal of Clinical and Analytical Medicine 2013;4(3):224-7.
23. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2]
24. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55(8):635-42.
25. Pang J, Chan HS, Sung JY. Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study. Thorax 1989;44(11):948-51.
26. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2004;170:400-7.
27. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
28. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine 2010;104(7):981-5.
29. Santamaria F, Montella S, Pifferi M, Ragazzo V, De SS, De PN, et al. A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. Respiration 2009;77(2):160-5.
30. Seitz AE, Olivier KN, Steiner CA, De Oca RM, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations: USA, 1993-2006. Chest 2010;138(4):944-9.
31. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002155]
32. Singleton RJ, Morris A, Redding G, Poll J, Holck P, Martinez P, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatric Pulmonology 2000;29(3):182-7.
33. Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1998;158(3):723-7.
34. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61:414-8.
35. Walker JK, Penn RB, Hanania NA, Dickey BF, Bond RA. New perspectives regarding beta(2) -adrenoceptor ligands in the treatment of asthma. British Journal of Pharmacology 2011;163(1):18-28.
36. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205-9.